Circular RNAs as diagnostic biomarkers in type 2 diabetes mellitus: implications in metabolic dysfunction and immune-inflammatory crosstalk - Takeaways - MDSpire

Circular RNAs as diagnostic biomarkers in type 2 diabetes mellitus: implications in metabolic dysfunction and immune-inflammatory crosstalk

  • By

  • Zhaoxia Liu

  • Hui Wu

  • Qiaoshuang Pu

  • Xiongtao Yang

  • Da Li

  • Shipin Feng

  • Yan Wang

  • May 15, 2026

Share

  • 1

    Circular RNAs (circRNAs) are stable, disease-specific molecules that may serve as diagnostic biomarkers for Type 2 diabetes mellitus (T2DM).

  • 2

    CircRNAs regulate key processes in T2DM, including insulin resistance, glucose uptake, and β-cell function through competing endogenous RNA networks.

  • 3

    Current diagnostic tools for T2DM often fail to capture early metabolic dysregulation, highlighting the need for sensitive, non-invasive biomarkers like circRNAs.

  • 4

    Challenges in circRNA research include sample size, cohort heterogeneity, and the need for rigorous validation to support their clinical application.

  • 5

    Future research should focus on multicenter studies and advanced transcriptomic technologies to integrate circRNAs into precision medicine for T2DM.

Original Source(s)

Circular RNAs as diagnostic biomarkers in type 2 diabetes mellitus: implications in metabolic dysfunction and immune-inflammatory crosstalk

  • by Zhaoxia Liu, Hui Wu, Qiaoshuang Pu, Xiongtao Yang, Da Li, Shipin Feng, Yan Wang

  • May 15, 2026

Related Content

CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.

FDA Clears AI Sepsis Warning System

An FDA-cleared AI tool developed at Johns Hopkins detects sepsis up to 48 hours earlier than clinicians — and has cut related deaths by 18%.